Dermatomyositis (DM) | Polymyositis (PM) | Cancer-associated myositis (CAM) | Healthy controls (HC) | |
---|---|---|---|---|
Number | 43 | 39 | 22 | 77 |
Gender, female/male | 35/8 | 25/14 | 20/2 | 58/19 |
Age, years | 58 (41 to 63) | 55 (36 to 60) | 64 (59 to 70) | 45 (31 to 54) |
S100A4, ng/ml | 26.7 (11.3 to 47.5) | 41.6 (24.2 to 123.1) | 28.8 (12.6 to 45.4) | 23.8 (14.5 to 33.7) |
S100A4, ng/ml in females | 26.7 (9.0 to 54.7) | 54.2 (25.4 to 115.6) | 28.8 (13.0 to 47.5) | 22.2 (13.6 to 32.1) |
S100A4, ng/ml in males | 30.3 (19.5 to 44.8) | 41.3 (23.9 to 157.9) | 20.3 (5.5 to 35.0) | 32.3 (19.9 to 64.6)* |
Disease duration, years | 2.4 (0.4 to 8.3) | 0.9 (0.5 to 3.2) | 0.6 (0.2 to 3.6) | NA |
Biochemical markers | ||||
CRP, mg/L | 3.3 (1.3 to 9.0) | 4.7 (2.2 to 26.1) | 8.0 (3.2 to 26.6) | NA |
CK, ukat/L | 2.6 (1.2 to 9.9) | 11.6 (2.0 to 29.3) | 10.9 (1.5 to 37.1) | NA |
LD, ukat/L | 4.4 (3.5 to 6.4) | 7.1 (4.2 to 10.9) | 5.2 (2.9 to 6.0) | NA |
Autoantibodies | 6*Mi-2 | 12*Jo-1; | 11*TIF1 | NA |
4*TIF1, 1*TIF1 + U1RNP | 1* Jo-1 + U1RNP; | 4*Mi-2 | ||
2*NXP2 | 1*Jo-1 + RNAPI + RNAPII | 2*Jo-1, 1*Jo-1 + Ro | ||
3*PM-Scl | 2*PM-Scl | 1*SAE | ||
3*Jo-1 | 1*PL7 | 3*without known aAbs | ||
19*without known aAbs | 1*Ku | |||
1*SRP | ||||
1*TIF1 + AMA | ||||
15*without known aAbs | ||||
Clinical features, number | ||||
Muscle weakness | 43 | 39 | 22 | NA |
Rash | 42 | 1 | 16 | NA |
Mechanic's hands | 18 | 10 | 8 | NA |
Raynaud's phenomenon | 9 | 10 | 3 | NA |
Arthritis | 14 | 14 | 4 | NA |
Interstitial lung disease | 15 | 22 | 5 | NA |
Cardiac involvement | 10 | 6 | 3 | NA |
Dysphagia | 21 | 15 | 10 | NA |
Disease activity | ||||
MYOACT | 0.6 (0.15 to 1.5) | 0.7 (0.2 to 1.3) | 0.8 (0.5 to 1.8) | NA |
Constitutional DA, VAS | 6 (0 to 18) | 8 (0 to 24) | 0 (0 to 28.5) | NA |
Cutaneous DA, VAS) | 15 (0 to 30) | 0 (0 to 6) | 28.5 (0 to 52.8) | NA |
Skeletal DA, VAS | 0 (0 to 0) | 0 (0 to 7) | 0 (0 to 2) | NA |
Gastrointestinal DA, VAS | 0 (0 to 4) | 0 (0to3) | 0 (0 to 25.5) | NA |
Pulmonary DA, VAS | 0 (0 to 7) | 6.5 (0 to 24.7) | 0 (0 to 13) | NA |
Cardiac DA, VAS | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | NA |
Extramuscular DA, VAS | 15 (4 to 34) | 17 (3.5 to 32.5) | 20 (11.5 to 54.5) | NA |
Muscle DA, VAS | 10 (3 to 44) | 32 (14 to 53) | 37 (5.5 to 68.3) | NA |
Physician's global disease Assessment, VAS | 19.5 (4.5 to 43.7) | 30.5 (22.5 to 49.3) | 42.5 (13.5 to 52) | NA |
HAQ | 1.0 (0.3 to 1.9) | 0.9 (0.5 to 1.3) | 1.0 (0.5 to 2.6) | NA |
MMT8 | 62 (52 to 74) | 71 (63 to 74.5) | 56 (50.5 to 69.0) | NA |
Treatment | ||||
Treatment duration, months | 13.6 (0.9 to 83.6) | 2.0 (0.3 to 72.1) | 1.4 (0.0 to 20.6) | NA |
Daily glucocorticoid dosage, mg prednisone equivalent | 10.0 (2.5 to 40.0) | 25.0 (3.8 to 50.0) | 6.3 (0.0 to 42.5) | NA |
Immunosuppressive drugs | 11*MTX, 3*Plaquenil, 2* AZA, 2*CyA, 23*no immunosuppressive drugs at the time of blood withdrawal, 2*before start of the immunosuppressive treatment | 10*MTX,1*MTX + AZA, 1*MTX + SAS, 4*CyA, 2*Plaquenil, 1*AZA, 15*no immunosuppressive drugs at the time of blood withdrawal, 5*before start of the immunosuppressive treatment | 4*MTX, 11*no immunosuppressive drugs at the time of blood withdrawal, 7*before start of the immunosuppressive treatment | NA |